Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Lorenzo D'AmbrosioNathan TouatiJean Yves BlayGiovanni GrignaniRonan FlippotAnna M CzarneckaSophie Piperno-NeumannJavier Martin-BrotoRoberta SanfilippoDaniela KatzFlorence DuffaudBruno VincenziDaniel P StarkFilomena MazzeoArmin TuchschererChristine ChevreauJenny SherriffAnna EstivalSaskia LitièreWard SentsIsabelle Ray-CoquardFrancesco TolomeoAxel Le CesnePiotr RutkowskiSilvia StacchiottiBernd KasperHans GelderblomAlessandro Gronchinull nullPublished in: Cancer (2020)
This is the largest retrospective study of first-line treatment for advanced leiomyosarcoma. In the propensity score-matched population, doxorubicin and dacarbazine showed favorable activity in terms of both ORR and PFS and warrants further evaluation in prospective trials.